Carregant...
Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
Trastuzumab emtansine (T-DM1), an antibody-drug conjugate consisted of the HER2-targeted monoclonal antibody trastuzumab and the tubulin inhibitor emtansine, has shown potent therapeutic value in HER2-positive breast cancer (BC). However, a clinical trial indicated that T-DM1 exerts a limited effect...
Guardat en:
| Publicat a: | Cell Death Dis |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7969610/ https://ncbi.nlm.nih.gov/pubmed/33731670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-03349-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|